Lymphoma & CLL Trials

Using ctDNA analysis in risk profiling of frontline DLBCL: Results from the POLARIX study

In the risk profiling of previously untreated patients with DLBCL from the POLARIX study using ctDNA, results...

Educational theme | Disease management of elderly patients with aggressive B-cell lymphoma in the modern era

Lymphoma Hub recently shared a brief insight on how to improve care for the elderly...

Zanubrutinib receives FDA approval for CLL and SLL

The U.S. Food and Drug Administration (FDA) has granted approval to zanubrutinib for the treatment of adult patients with chronic lymphocytic...

Zanubrutinib versus ibrutinib in R/R CLL/SLL: final ALPINE results

Final results of the ALPINE trial were presented by Jennifer Brown at the late-breaking abstracts session of #ASH22. Zanubrutinib...

Novel therapies in chronic lymphocytic leukemia: An update

During the 64th ASH Annual Meeting and Exposition, the Lymphoma Hub spoke to Chan Cheah, University of Western Australia, Perth, AU. We asked...

BRUIN trial: Phase I/II of pirtobrutinib, a novel, reversible BTK inhibitor for relapsed B-cell malignancies

When treating B cell-malignancies, covalent inhibitors correspond to the most frequently...

Mosunetuzumab receives FDA approval for the treatment of R/R follicular lymphoma

On December 22, 2022, it was announced that mosunetuzumab, a CD20 × CD3 T-cell engaging bispecific antibody, had...

Mosunetuzumab receives European Commission approval for the treatment of relapsed or refractory follicular lymphoma

On June 8, 2022, it was announced that the European Commission (EC) has granted...